Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00077168
Status:
UNKNOWN
Last Update Posted:
2009-02-09
First Post:
2004-02-10
Brief Title:
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
Sponsor:
Institute of Cancer Research United Kingdom
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Randomised Trial Testing Observation No Radiotherapy Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ DCIS Of The Breast On Adjuvant Endocrine Therapy
Status:
UNKNOWN
Status Verified Date:
2007-10
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Radiation therapy uses high-energy x-rays to damage tumor cells It is not yet known whether radiation therapy after surgery is effective in preventing a recurrence of ductal carcinoma in situ
PURPOSE This randomized phase II trial is studying adjuvant radiation therapy to see how well it works compared to observation after surgery in treating women with estrogen receptor positive or progesterone receptor positive ductal carcinoma in situ and are also receiving either tamoxifen or anastrozole
PURPOSE This randomized phase II trial is studying adjuvant radiation therapy to see how well it works compared to observation after surgery in treating women with estrogen receptor positive or progesterone receptor positive ductal carcinoma in situ and are also receiving either tamoxifen or anastrozole
Detailed Description:
OBJECTIVES
Primary
Compare ipsilateral tumor relapse and breast cancer metastases in women with completely excised low-risk estrogen receptor- or progesterone receptor-positive ductal carcinoma in situ of the breast receiving adjuvant tamoxifen or anastrozole and treated with adjuvant radiotherapy vs observation alone
Compare the quality of life of patients treated with these regimens
Secondary
Determine the minimal surgical margins required to minimize the local recurrence rate in patients treated with these regimens
Identify molecular markers that predict ipsilateral tumor recurrence in patients treated with these regimens
OUTLINE This is a randomized multicenter study Patients are stratified according to participating center Patients are randomized to 1 of 2 treatment arms
All patients receive adjuvant tamoxifen or anastrozole for 5 years
Arm I Patients undergo radiotherapy 5 days a week for 3 or 5 weeks
Arm II Patients undergo observation alone Quality of life is assessed at baseline at 6 months and then at 1 2 and 5 years
Patients are followed every 6 months for 1 year and then annually for up to 10 years
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL A total of 2000 patients 1000 per treatment arm will be accrued for this study within 5 years
Primary
Compare ipsilateral tumor relapse and breast cancer metastases in women with completely excised low-risk estrogen receptor- or progesterone receptor-positive ductal carcinoma in situ of the breast receiving adjuvant tamoxifen or anastrozole and treated with adjuvant radiotherapy vs observation alone
Compare the quality of life of patients treated with these regimens
Secondary
Determine the minimal surgical margins required to minimize the local recurrence rate in patients treated with these regimens
Identify molecular markers that predict ipsilateral tumor recurrence in patients treated with these regimens
OUTLINE This is a randomized multicenter study Patients are stratified according to participating center Patients are randomized to 1 of 2 treatment arms
All patients receive adjuvant tamoxifen or anastrozole for 5 years
Arm I Patients undergo radiotherapy 5 days a week for 3 or 5 weeks
Arm II Patients undergo observation alone Quality of life is assessed at baseline at 6 months and then at 1 2 and 5 years
Patients are followed every 6 months for 1 year and then annually for up to 10 years
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL A total of 2000 patients 1000 per treatment arm will be accrued for this study within 5 years
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EU-20341 | None | None | None |
| ICR-DCIS-II | None | None | None |